Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8440739rdf:typepubmed:Citationlld:pubmed
pubmed-article:8440739lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:8440739lifeskim:mentionsumls-concept:C1512977lld:lifeskim
pubmed-article:8440739lifeskim:mentionsumls-concept:C0003404lld:lifeskim
pubmed-article:8440739lifeskim:mentionsumls-concept:C0016411lld:lifeskim
pubmed-article:8440739lifeskim:mentionsumls-concept:C0034283lld:lifeskim
pubmed-article:8440739lifeskim:mentionsumls-concept:C1444748lld:lifeskim
pubmed-article:8440739lifeskim:mentionsumls-concept:C0683598lld:lifeskim
pubmed-article:8440739lifeskim:mentionsumls-concept:C1880022lld:lifeskim
pubmed-article:8440739pubmed:issue6lld:pubmed
pubmed-article:8440739pubmed:dateCreated1993-3-26lld:pubmed
pubmed-article:8440739pubmed:abstractTextWe describe the characterization of an antitumor drug resistance following multiple step selection of hamster cells to the 2,4-diaminopyrimidines (DAP) metoprine, pyrimethamine (Pyr), and trimethoprim (Tmp). Pyr and Tmp are DAP lipophilic antifolates currently used as antiparasitic and antibacterial antibiotics, respectively. Dihydrofolate reductase (DHFR) from hamster cells bore a low or poor affinity to these DAP as compared to the hydrophilic folate antagonist methotrexate (MTX). Metoprine-resistant cells over-expressed DHFR enzyme and consequently displayed a high level of resistance to both hydrophilic and lipophilic antifolates including DAP but maintained wild type sensitivity to pleiotropic drugs involved in multi-drug resistance (MDR). In contrast, although Pyr- and Tmp-resistant cells expressed parental levels of wild type DHFR, they displayed a high degree of resistance to DAP and, surprisingly, to the lipophilic MTX analogs piritrexim (PTX) and trimetrexate (TMTX), while maintaining sensitivity to MTX. These drug-resistant cells maintained wild type mRNA levels of the MDR gene product P-glycoprotein and showed collateral hypersensitivity to pleiotropic drugs. To study the underlying mechanism of this apparently new resistance phenotype, we have employed fluorescein-methotrexate (F-MTX) labeling of cells and its displacement by different antifolates. Parental AA8 and Pyr-resistant cells showed a similar level of F-MTX labeling, however, while DAP, TMTX, and PTX showed an efficient competitive displacement of F-MTX from AA8 cells, Pyr-resistant cells displayed a persistent retention of F-MTX labeling in the presence of high concentrations of these lipophilic antifolates. Pyr-resistant cells showed a wild type displacement of F-MTX with MTX. This DAP resistance phenotype was unstable as it was rapidly lost upon growth under nonselective conditions. Furthermore, when the antifolate resistance levels of Pyr-resistant cells were plotted versus the ratios of the 50% F-MTX displacement values obtained with resistant and parental AA8 cells, a good correlation (r2 > 0.98) was obtained. We conclude that Pyr-resistant cells possess a novel phenotype that derives its resistance to lipophilic antifolates solely from a predominant decrease in the accumulation of DAP and lipid-soluble analogs of MTX.lld:pubmed
pubmed-article:8440739pubmed:languageenglld:pubmed
pubmed-article:8440739pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8440739pubmed:citationSubsetIMlld:pubmed
pubmed-article:8440739pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8440739pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8440739pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8440739pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8440739pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8440739pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8440739pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8440739pubmed:statusMEDLINElld:pubmed
pubmed-article:8440739pubmed:monthFeblld:pubmed
pubmed-article:8440739pubmed:issn0021-9258lld:pubmed
pubmed-article:8440739pubmed:authorpubmed-author:AssarafY GYGlld:pubmed
pubmed-article:8440739pubmed:authorpubmed-author:SlotkyJ IJIlld:pubmed
pubmed-article:8440739pubmed:issnTypePrintlld:pubmed
pubmed-article:8440739pubmed:day25lld:pubmed
pubmed-article:8440739pubmed:volume268lld:pubmed
pubmed-article:8440739pubmed:geneSymbolDHFRlld:pubmed
pubmed-article:8440739pubmed:ownerNLMlld:pubmed
pubmed-article:8440739pubmed:authorsCompleteYlld:pubmed
pubmed-article:8440739pubmed:pagination4556-66lld:pubmed
pubmed-article:8440739pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8440739pubmed:meshHeadingpubmed-meshheading:8440739-...lld:pubmed
pubmed-article:8440739pubmed:meshHeadingpubmed-meshheading:8440739-...lld:pubmed
pubmed-article:8440739pubmed:meshHeadingpubmed-meshheading:8440739-...lld:pubmed
pubmed-article:8440739pubmed:meshHeadingpubmed-meshheading:8440739-...lld:pubmed
pubmed-article:8440739pubmed:meshHeadingpubmed-meshheading:8440739-...lld:pubmed
pubmed-article:8440739pubmed:meshHeadingpubmed-meshheading:8440739-...lld:pubmed
pubmed-article:8440739pubmed:meshHeadingpubmed-meshheading:8440739-...lld:pubmed
pubmed-article:8440739pubmed:meshHeadingpubmed-meshheading:8440739-...lld:pubmed
pubmed-article:8440739pubmed:meshHeadingpubmed-meshheading:8440739-...lld:pubmed
pubmed-article:8440739pubmed:meshHeadingpubmed-meshheading:8440739-...lld:pubmed
pubmed-article:8440739pubmed:meshHeadingpubmed-meshheading:8440739-...lld:pubmed
pubmed-article:8440739pubmed:meshHeadingpubmed-meshheading:8440739-...lld:pubmed
pubmed-article:8440739pubmed:year1993lld:pubmed
pubmed-article:8440739pubmed:articleTitleCharacterization of a lipophilic antifolate resistance provoked by treatment of mammalian cells with the antiparasitic agent pyrimethamine.lld:pubmed
pubmed-article:8440739pubmed:affiliationDepartment of Biology, Technion-Israel Institute of Technology, Haifa.lld:pubmed
pubmed-article:8440739pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8440739pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8440739lld:pubmed